Back to search results
NCT06848361

Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management

Enrolling by Invitation
NAAges 25–75Interventional
Ann-Marie Rosland
~80 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:MPowerHubContinuous Glucose Monitor (CGM)Activity Monitor

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent of eligible individuals who enroll in the study
Measured over Pre-baseline
+2 more outcomes measured

Conditions

Type 2 Diabetes Mellitus (T2DM)

Explore related trials

Type 2 Diabetes MellitusHemoglobin A, Glycosylated

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Ann-Marie Rosland, MD, MS · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
  • Carissa Low, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Received outpatient care in the participating health system in the last 12 months
Has a diagnosis of type 2 diabetes mellitus (ICD10 codes E08.xx, E09.xx, E11.xx, E13.xx,O24.1x , O24.3x, O24.8x, O24.9x)
Last Hemoglobin A1c (HbA1c) value obtained in the last 6 months was ≥7.5%
Currently prescribed at least one non-insulin diabetes medication
Able to provide informed consent
Able to interact with a simple smartphone application
Owns or has access to a smartphone that is able to access an internet website
Did not participate a prior study related to this protocol

Exclusion

Originally was diagnosed with type 2 diabetes before the age of 21 years
Has a diagnosis of type 1 diabetes mellitus
Has a diagnosis of gestational diabetes without any other diabetes diagnoses
Is currently prescribed insulin
Currently is using a CGM device
Has a diagnosis (active or prior) of schizophrenia or other psychotic/delusional disorder
Has a life-limiting severe illness (e.g., chronic obstructive pulmonary disease requiring oxygen)
Is pregnant or planning to become pregnant within the next 6 months
Has other concerns that may interfere significantly with their ability to participate in the intervention (ongoing health issues, personal events, etc.)
Currently is enrolled in another diabetes management intervention study

What this trial measures

  • Percent of eligible individuals who enroll in the studyPre-baseline

    Percent of individuals contacted and found eligible who enroll in the study. The goal benchmark is \>/=60%.

  • Percent of days wearable device data is collectedFrom 0 to 4 months

    Percent of days adequate wearable device data is collected during the 4-month intervention. The goal benchmark is \>/=75%.

  • Percent participants retained in study to the 4-month outcome assessmentFrom 0 to 4 months

    Percent of participants retained in the study through the 4-month outcome assessment. The goal benchmark is \>/=85%.